Induction of potent neutralizing antibody responses by a designed protein nanoparticle accine for respiratory syncytial virus
-
Marcandalli, Jessica
Institute for Research in Biomedicine (IRB), Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland -
-
Fiala, Brooke
Department of Biochemistry, University of Washington, Seattle, USA - Institute for Protein Design, University of Washington, Seattle, USA
-
Ols, Sebastian
Department of Medicine Solna, Division of Immunology and Allergy, Karolinska Institutet, Stockholm, Sweden - Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden
-
Perotti, Michela
Institute for Research in Biomedicine (IRB), Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland - Institute of Microbiology, ETH Zürich, Switzerland
-
de van der Schueren, Willem
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, USA - Bluebird Bio, Seattle, USA
-
Snijder, Joost
Department of Biochemistry, University of Washington, Seattle, USA
-
Hodge, Edgar
Department of Medicinal Chemistry, University of Washington, Seattle, USA
-
Benhaim, Mark
Department of Medicinal Chemistry, University of Washington, Seattle, USA
-
Ravichandran, Rashmi
Department of Biochemistry, University of Washington, Seattle, USA - Institute for Protein Design, University of Washington, Seattle, USA
-
Carter, Lauren
Department of Biochemistry, University of Washington, Seattle, USA - Institute for Protein Design, University of Washington, Seattle, USA
-
Sheffler, Will
Department of Biochemistry, University of Washington, Seattle, USA - Institute for Protein Design, University of Washington, Seattle, USA
-
Brunner, Livia
Vaccine Formulation Laboratory, University of Lausanne, Switzerland
-
Lawrenz, Maria
Vaccine Formulation Institute, Godalming, UK
-
Dubois, Patrice
Vaccine Formulation Institute, Godalming, UK
-
Lanzavecchia, Antonio
Institute for Research in Biomedicine (IRB), Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland
-
Sallusto, Federica
Institute for Research in Biomedicine (IRB), Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland - Institute of Microbiology, ETH Zürich, Switzerland
-
Lee, Kelly K.
Department of Medicinal Chemistry, University of Washington, Seattle, USA - Biological Physics Structure and Design Program, University of Washington, Seattle, USA
-
Veesler, David
Department of Biochemistry, University of Washington, Seattle, USA
-
Correnti, Colin E.
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, USA
-
Stewart, Lance J.
Department of Biochemistry, University of Washington, Seattle, USA - Institute for Protein Design, University of Washington, Seattle, USA
-
Baker, David
Department of Biochemistry, University of Washington, Seattle, USA - Institute for Protein Design, University of Washington, Seattle, USA - Howard Hughes Medical Institute, University of Washington, Seattle, USA
-
Loré, Karin
Department of Medicine Solna, Division of Immunology and Allergy, Karolinska Institutet, Stockholm, Sweden - Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden
-
Perez, Laurent
Institute for Research in Biomedicine (IRB), Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland - European Virus Bioinformatics Center, Jena, Germany
-
King, Neil P.
Department of Biochemistry, University of Washington, Seattle, USA - Institute for Protein Design, University of Washington, Seattle, USA
Show more…
Published in:
- Cell. - 2019, vol. 177, no. 6, p. 1420-1431.e17
English
Respiratory syncytial virus (RSV) is a worldwide public health concern for which no vaccine is available. Elucidation of the prefusion structure of the RSV F glycoprotein and its identification as the main target of neutralizing antibodies have provided new opportunities for development of an effective vaccine. Here, we describe the structure-based design of a self-assembling protein nanoparticle presenting a prefusion-stabilized variant of the F glycoprotein trimer (DS-Cav1) in a repetitive array on the nanoparticle exterior. The two-component nature of the nanoparticle scaffold enabled the production of highly ordered, monodisperse immunogens that display DS-Cav1 at controllable density. In mice and nonhuman primates, the full-valency nanoparticle immunogen displaying 20 DS-Cav1 trimers induced neutralizing antibody responses ∼10-fold higher than trimeric DS-Cav1. These results motivate continued development of this promising nanoparticle RSV vaccine candidate and establish computationally designed two-component nanoparticles as a robust and customizable platform for structure-based vaccine design.
-
Language
-
-
Classification
-
Pathology, clinical medicine
-
License
-
License undefined
-
Identifiers
-
-
Persistent URL
-
https://n2t.net/ark:/12658/srd1318938
Statistics
Document views: 100
File downloads:
- Marcandalli_Cell_2019.pdf: 204